WO2016025933A3 - Substituted polycyclic antibacterial compounds - Google Patents

Substituted polycyclic antibacterial compounds Download PDF

Info

Publication number
WO2016025933A3
WO2016025933A3 PCT/US2015/045433 US2015045433W WO2016025933A3 WO 2016025933 A3 WO2016025933 A3 WO 2016025933A3 US 2015045433 W US2015045433 W US 2015045433W WO 2016025933 A3 WO2016025933 A3 WO 2016025933A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
neisseria
substituted polycyclic
forms
Prior art date
Application number
PCT/US2015/045433
Other languages
French (fr)
Other versions
WO2016025933A2 (en
Inventor
Jiashi WANG
Aleksey Igorevich GERASYUTO
Michael A. ARNOLD
Gary Mitchell Karp
Hongyan Qi
Matthew G. WOLL
Nanjing Zhang
Arthur A. Branstrom
Jana Narasimhan
Melissa L. DUMBLE
Jean Hedrick
Maria L. WEETALL
Original Assignee
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics, Inc. filed Critical Ptc Therapeutics, Inc.
Publication of WO2016025933A2 publication Critical patent/WO2016025933A2/en
Publication of WO2016025933A3 publication Critical patent/WO2016025933A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present description relates to substituted polycyclic compounds and forms and pharmaceutical compositions thereof and methods of using such compounds, forms or compositions thereof for treating or ameliorating Neisseria gonorrhoeae and Neisseria meningiditis. The present description relates to a compound of Formula (I), Formula (II), Formula (III) or Formula (IV): wherein the dashed line "----- " represents an optional double bond and R1, R2, R5, X and Z are as defined herein, and forms and compositions thereof, and also relates to uses of a compound of Formula (I), Formula (II), Formula (III) or Formula (IV) or a form thereof and methods for treating or ameliorating Neisseria gonorrhoeae (N. gonorrhoeae) or Neisseria meningitidis (N. meningitidis) in a subject in need thereof, comprising, administering an effective amount of the compound to the subject.
PCT/US2015/045433 2014-08-15 2015-08-15 Substituted polycyclic antibacterial compounds WO2016025933A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038135P 2014-08-15 2014-08-15
US62/038,135 2014-08-15

Publications (2)

Publication Number Publication Date
WO2016025933A2 WO2016025933A2 (en) 2016-02-18
WO2016025933A3 true WO2016025933A3 (en) 2016-04-07

Family

ID=55304771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/045433 WO2016025933A2 (en) 2014-08-15 2015-08-15 Substituted polycyclic antibacterial compounds

Country Status (1)

Country Link
WO (1) WO2016025933A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
KR102556744B1 (en) 2017-08-28 2023-07-18 이난타 파마슈티칼스, 인코포레이티드 Hepatitis B antivirals
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
CA3113235A1 (en) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) * 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN115057845B (en) * 2022-06-14 2024-05-03 山东罗欣药业集团恒欣药业有限公司 Preparation method of arbeli

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299963A (en) * 1977-03-08 1981-11-10 Takeda Chemical Industries, Ltd. 1-Azaxanthone derivatives
WO2008127274A2 (en) * 2006-09-22 2008-10-23 Ptc Therapeutics, Inc. Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
WO2013033228A1 (en) * 2011-08-29 2013-03-07 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
WO2014022613A1 (en) * 2012-08-01 2014-02-06 Musc Foundation For Research Development Antibacterial compositions and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299963A (en) * 1977-03-08 1981-11-10 Takeda Chemical Industries, Ltd. 1-Azaxanthone derivatives
WO2008127274A2 (en) * 2006-09-22 2008-10-23 Ptc Therapeutics, Inc. Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
WO2013033228A1 (en) * 2011-08-29 2013-03-07 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
WO2014022613A1 (en) * 2012-08-01 2014-02-06 Musc Foundation For Research Development Antibacterial compositions and methods

Also Published As

Publication number Publication date
WO2016025933A2 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
WO2016025933A3 (en) Substituted polycyclic antibacterial compounds
WO2017100726A8 (en) Methods for treating huntington's disease
BR112017003658A2 (en) compound, mixture, methods for treating a disease and for inhibiting a glycosidase; and, pharmaceutical composition.
MX2016011898A (en) Compositions of selenoorganic compounds and methods of use thereof.
MX2015015412A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
GEP201706748B (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
TN2014000254A1 (en) Substituted triazolopyridines and their use as ttk inhibitors
PH12015502324A1 (en) Synergistic compositions
MX2020003112A (en) Biguanide compositions and methods of treating metabolic disorders.
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
JO3040B1 (en) Triazolopyridines
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
BR112017005242A2 (en) compound, pharmaceutical composition, and compound for use.
MX2022000945A (en) Composition for increasing expression of pgc-1î±.
MX2016004963A (en) Salt and crystal forms of plk-4 inhibitor.
MY192545A (en) Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
MX2020006434A (en) Novel mtor inhibitor compounds.
PH12019500822A1 (en) Crystalline forms of eravacycline
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
MX2020006436A (en) Mtor inhibitor compounds.
MX2017008076A (en) Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors.
WO2017106367A8 (en) Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15832499

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15832499

Country of ref document: EP

Kind code of ref document: A2